
DSM Special Products sale to Arsenal fails
The sale of chemicals business DSM Special Products BV to US-based Arsenal Capital Partners will not be completed due to provisions imposed by the European Commission. The deal was originally announced on 3 March 2008.
In August 2008, the European Commission announced an in-depth investigation into the transaction. Last month, the European Commission approved the sale, but the conditions the Commission demanded have led to the conclusion that the intended sale is no longer feasible. DSM will continue the divestment process for DSM Special Products, as part of its Vision 2010 strategy.
DSM Special Products is the producer of Purox(R), an ingredient used in food as well as in a range of industrial applications. It also produces an ingredient for VevoVitall(R), a product for the animal health market that will remain with DSM Nutritional Products. DSM Special Products employs around 130 people in Rotterdam and Sittard (Netherlands), and has an annual turnover of approximately EUR100m.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater